{"transactions":[{"id":947015,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-07T01:00:05.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":2500,"derivative":{"exercise_price":2.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001493152-26-000694","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226000694/ownership.xml","form_type":"4"}},{"id":1303563,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-14T23:57:00.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":5000,"derivative":{"exercise_price":1.38,"expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-25-000412","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000412/section16.xml","form_type":"4"}},{"id":1685678,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-06T02:00:44.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 4, 2024."}],"balance_after":10000,"derivative":{"exercise_price":0.6099,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001654954-24-000292","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424000292/section16.xml","form_type":"4"}},{"id":1819788,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-01T17:22:18.000Z","date":"2023-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":86301,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Stock options of the Issuer (the \"Company Options\") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration,"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options of the Issuer (the \"Company Options\") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Stock options of the Issuer (the \"Company Options\") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.13,"underlying":"Common Stock","underlying_shares":86301},"source":{"system":"sec-edgar","filing":"0000899243-23-017680","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/831547/000089924323017680/doc4.xml","form_type":"4"}},{"id":1819787,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2023-08-01T17:22:18.000Z","date":"2023-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27380,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 24, 2023, by and among the Issuer, Assertio Holdings, Inc., a Delaware corporation (\"Acquiror\"), and Spade Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Acquiror, in exchange for consideration of (a) 0.1783 of a share of the common stock of Acquiror and cash in lieu of fractional shares (the \"Upfront Consideration\") and (b) a contingent value right (\"CVR\") to receive up to an additional $0.20 per common share (subject to adjustment), payable in cash or common stock of Acquiror at the election of Acquiror, upon the achievement of certain milestones, (the Upfront Consideration plus one CVR, collectively, the \"Merger Consideration\") on the effective date of the merger."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-017680","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/831547/000089924323017680/doc4.xml","form_type":"4"}},{"id":2140570,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-10-07T21:06:13.000Z","date":"2022-10-06","kind":"grant","acquired":true,"shares":9810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On October 6, 2022, the Reporting Person was granted 9,810 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":23443,"source":{"system":"sec-edgar","filing":"0001654954-22-013529","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422013529/section16.xml","form_type":"4"}},{"id":2168320,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-02T16:15:46.000Z","date":"2022-08-31","kind":"grant","acquired":true,"shares":86301,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the aggregate amount of option shares shall vest on each of August 31, 2023, 2024 and 2025, respectively."}],"balance_after":86301,"derivative":{"exercise_price":1.13,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":86301},"source":{"system":"sec-edgar","filing":"0001209191-22-048497","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/831547/000120919122048497/doc4.xml","form_type":"4"}},{"id":2168319,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2022-09-02T16:15:46.000Z","date":"2022-08-31","kind":"grant","acquired":true,"shares":27380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on August 31, 2022. One hundred percent (100%) of the total number of RSUs granted vest on the earlier of (i) June 22, 2023 or (ii) the date of the Company's 2023 Annual Meeting of Stockholders."}],"balance_after":27380,"source":{"system":"sec-edgar","filing":"0001209191-22-048497","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/831547/000120919122048497/doc4.xml","form_type":"4"}},{"id":2210010,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2022-07-08T20:10:24.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":8602,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 7, 2022, the Reporting Person was granted 8,602 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":13633,"source":{"system":"sec-edgar","filing":"0001654954-22-009456","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422009456/section16.xml","form_type":"4"}},{"id":2300462,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2022-04-08T23:13:41.000Z","date":"2022-04-07","kind":"grant","acquired":true,"shares":5031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 7, 2022, the Reporting Person was granted 5,031 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":5031,"source":{"system":"sec-edgar","filing":"0000905718-22-000564","document":"dermata_fm4apr72022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000564/dermata_fm4apr72022.xml","form_type":"4"}},{"id":2435097,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":70030,"kind":"person","name":"Bradrick Brittany","position":1,"cik":"0001904176","reported_name":"Bradrick Brittany","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to Buy)","published_at":"2022-01-14T22:10:48.000Z","date":"2022-01-12","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing on January 12, 2022."}],"balance_after":10000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-01-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000905718-22-000113","document":"dermata_fm4jan122022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000113/dermata_fm4jan122022.xml","form_type":"4"}}]}